• sales@syndicatedanalytics.com
  • +1-213-316-7435

GCC HIV Drugs Market by Drug Class (Nucleoside Reverse Transcriptase Inhibitors, Multi-Class Combination Products, Protease Inhibitors, HIV Integrase Strand Transfer Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Entry Inhibitors — CCR5 Co-Receptor Antagonist and Fusion Inhibitors) and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others): Industry Analysis, Trends, Growth and Forecast 2019-2024



GCC HIV Drugs Market Overview:

The GCC HIV drugs market was worth US$ XX Billion in 2018, expanding at a CAGR of X% during 2011-2018. The market is projected to register a CAGR of X% during 2019-2024, reaching US$ XX Billion by 2024.The GCC HIV drugs market is currently exhibiting strong growth rates. Human immunodeficiency virus, or HIV, is one of the major diseases of the 21st century. There has been a significant rise in the number of people suffering from HIV. HIV drugs can be used to control HIV virus from spreading throughout the body if detected at an early stage. The HIV diagnosis rate is increasing and therefore, HIV drugs along with effective and affordable therapies are continuously being developed. The rising awareness among people regarding the disease is playing a major driver for the growth of the HIV drugs market. Moreover, there is an increase in the government initiatives for spreading the awareness amongst people about its causes, symptoms and treatments to minimize the burden of HIV. In addition, the increasing adoption of generic drugs, because of their cost-effectiveness and easy affordability, by low-income groups is also driving the HIV drugs market in the GCC countries.

GCC HIV Drugs Market Segment Insights:

The report has assessed the GCC HIV drugs market on the basis of drug class covering,  nucleoside reverse transcriptase inhibitors, multi-class combination products, protease inhibitors, HIV integrase strand transfer inhibitors, non-nucleoside reverse transcriptase inhibitors, entry inhibitors — CCR5 co-receptor antagonist and fusion inhibitors. The report has further examined the market based on distribution channel including, hospital pharmacies, retail pharmacies, online pharmacies and others. On a regional basis, the report examines the HIV drugs market in Saudi Arabia, United Arab Emirates, Qatar, Kuwait, Oman and Bahrain. An evaluation of the competitive landscape has also been provided with the details of the key players operating in the GCC HIV drugs market.

Highlights of the GCC HIV Drugs Market Report:

  • Historical and current scenario
  • Trends and developments
  • Market forecast
  • Price analysis and forecast
  • Porter’s five forces analysis
  • SWOT analysis
  • Value chain analysis

Key Market Segments:

The GCC HIV Drugs market has been analysed as followed:

Segmentation by Drug Class:

  • Nucleoside Reverse Transcriptase Inhibitors
  • Multi-Class Combination Products
  • Protease Inhibitors
  • HIV Integrase Strand Transfer Inhibitors
  • Non-Nucleoside Reverse Transcriptase Inhibitors 
  • Entry Inhibitors — CCR5 Co-Receptor Antagonist
  • Fusion Inhibitors

Segmentation by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Segmentation by Country:

  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Kuwait
  • Oman
  • Bahrain

Report Customisation:

The GCC HIV drugs market report can be customised as per your requirements. You can get in touch with our analyst, who will make sure that the report suits your research needs.

 

1 Introduction
    1.1    Research Objectives 
    1.2    Stakeholders
    1.3    Scope of the Report
    1.4    Assumptions and Limitations
2 Research Methodology 
    2.1    Data Collection
            2.1.1    Primary Sources
            2.1.2    Secondary Sources
    2.2    Market Size Estimation
            2.2.1    Bottom-Up Approach
            2.2.2    Top-Down Approach
    2.3    Data Validation
3 Executive Summary
4 Global HIV Drugs Market

    4.1    Historical Market Trend
    4.2    Market Segmentation by Region
    4.3    Market Outlook
5 GCC HIV Drugs Market
    5.1    Industry Overview 
    5.2    Key Industry Developments
    5.3    Market Trends
            5.3.1    Key Market Indicators
            5.3.2    Historical Market Trends
            5.3.3    Market Outlook
6 GCC HIV Drugs Market Segmentation by Country
    6.1    Saudi Arabia  
            6.1.1    Historical Market Trends
            6.1.2    Market Outlook
    6.2    United Arab Emirates   
            6.2.1    Historical Market Trends
            6.2.2    Market Outlook
    6.3    Qatar 
            6.3.1    Historical Market Trends
            6.3.2    Market Outlook
    6.4    Kuwait 
            6.4.1    Historical Market Trends
            6.4.2    Market Outlook
    6.5    Oman  
            6.5.1    Historical Market Trends
            6.5.2    Market Outlook
    6.6    Bahrain  
            6.6.1    Historical Market Trends
            6.6.2    Market Outlook
7 GCC HIV Drugs Market Segmentation by Drug Class
    7.1    Nucleoside Reverse Transcriptase Inhibitors
            7.1.1    Historical Market Trends
            7.1.2    Market Outlook
    7.2    Multi-Class Combination Products
            7.2.1    Historical Market Trends
            7.2.2    Market Outlook
    7.3    Protease Inhibitors
             7.3.1    Historical Market Trends
             7.3.2    Market Outlook
    7.4    HIV Integrase Strand Transfer Inhibitors
             7.4.1    Historical Market Trends
             7.4.2    Market Outlook
    7.5    Non-Nucleoside Reverse Transcriptase Inhibitors 
            7.5.1    Historical Market Trends
            7.5.2    Market Outlook
    7.6    Entry Inhibitors — CCR5 Co-Receptor Antagonist
             7.6.1    Historical Market Trends
             7.6.2    Market Outlook
    7.7    Fusion Inhibitors
             7.7.1    Historical Market Trends
             7.7.2    Market Outlook
8 GCC HIV Drugs Market Segmentation by Distribution Channel
    8.1    Hospital Pharmacies
             8.1.1    Historical Market Trends
             8.1.2    Market Outlook
    8.2    Retail Pharmacies    
             8.2.1    Historical Market Trends
             8.2.2    Market Outlook
    8.3    Online Pharmacies
             8.3.1    Historical Market Trends
             8.3.2    Market Outlook
    8.4   Others    
            8.4.1    Historical Market Trends
            8.4.2    Market Outlook
9 GCC HIV Drugs Industry: Market Dynamics
    9.1    Overview
    9.2    Strengths
    9.3    Weaknesses 
    9.4    Opportunities
    9.5    Threats
10 GCC HIV Drugs Industry: Value Chain Analysis
    10.1   Overview
    10.2   Research and Development
    10.3   Raw Material Suppliers
    10.4   Inbound Logistics
    10.5   Production
    10.6   Marketing 
    10.7   Outbound Logistics
    10.8   Consumers 
11 GCC HIV Drugs Industry: Porter’s Five Forces Analysis
    11.1   Overview
    11.2   Threat of New Entrants
    11.3   Threat of Substitutes
    11.4   Bargaining Power of Buyers
    11.5   Bargaining Power of Suppliers
    11.6   Intensity of Rivalry
12 Competitive Landscape
    12.1   Market Structure
    12.2   Key Players 
    12.3   Key Success Factors 
13 Key Player Profiles
 
List of Figures

Figure 1: Global: HIV Drugs Market: Sales Value (in Billion US$), 2011-2018
Figure 2: Global: HIV Drugs Market: Segmentation by Region (in %), 2018
Figure 3: Global: HIV Drugs Market Outlook: Sales Value (in Billion US$), 2019-2024
Figure 4: GCC: HIV Drugs Market: Sales Value (in Billion US$), 2011-2018
Figure 5: GCC: HIV Drugs Market Outlook: Sales Value (in Billion US$), 2019-2024
Figure 6: GCC: HIV Drugs Market: Segmentation by Country (in %), 2018
Figure 7: GCC: HIV Drugs Market: Segmentation by Drug Class (in %), 2018
Figure 8: GCC: HIV Drugs Market: Segmentation by Distribution Channel (in %), 2018
Figure 9: Saudi Arabia: HIV Drugs Market: Sales Value (in Million US$), 2011 & 2018
Figure 10: Saudi Arabia: HIV Drugs Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 11: United Arab Emirates: HIV Drugs Market: Sales Value (in Million US$), 2011 & 2018
Figure 12: United Arab Emirates: HIV Drugs Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 13: Qatar: HIV Drugs Market: Sales Value (in Million US$), 2011 & 2018
Figure 14: Qatar: HIV Drugs Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 15: Kuwait: HIV Drugs Market: Sales Value (in Million US$), 2011 & 2018
Figure 16: Kuwait: HIV Drugs Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 17: Oman: HIV Drugs Market: Sales Value (in Million US$), 2011 & 2018
Figure 18: Oman: HIV Drugs Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 19: Bahrain: HIV Drugs Market: Sales Value (in Million US$), 2011 & 2018
Figure 20: Bahrain: HIV Drugs Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 21: GCC: HIV Drugs (Nucleoside Reverse Transcriptase Inhibitors) Market: Sales Value (in Million US$), 2011 & 2018
Figure 22: GCC: HIV Drugs (Nucleoside Reverse Transcriptase Inhibitors) Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 23: GCC: HIV Drugs (Multi-Class Combination Products) Market: Sales Value (in Million US$), 2011 & 2018
Figure 24: GCC: HIV Drugs (Multi-Class Combination Products) Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 25: GCC: HIV Drugs (Protease Inhibitors) Market: Sales Value (in Million US$), 2011 & 2018
Figure 26: GCC: HIV Drugs (Protease Inhibitors) Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 27: GCC: HIV Drugs (HIV Integrase Strand Transfer Inhibitors) Market: Sales Value (in Million US$), 2011 & 2018
Figure 28: GCC: HIV Drugs (HIV Integrase Strand Transfer Inhibitors) Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 29: GCC: HIV Drugs (Non-Nucleoside Reverse Transcriptase Inhibitors) Market: Sales Value (in Million US$), 2011 & 2018
Figure 30: GCC: HIV Drugs (Non-Nucleoside Reverse Transcriptase Inhibitors) Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 31: GCC: HIV Drugs (Entry Inhibitors — CCR5 Co-Receptor Antagonist) Market: Sales Value (in Million US$), 2011 & 2018
Figure 32: GCC: HIV Drugs (Entry Inhibitors — CCR5 Co-Receptor Antagonist) Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 33: GCC: HIV Drugs (Fusion Inhibitors) Market: Sales Value (in Million US$), 2011 & 2018
Figure 34: GCC: HIV Drugs (Fusion Inhibitors) Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 35: GCC: HIV Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2011 & 2018
Figure 36: GCC: HIV Drugs (Hospital Pharmacies) Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 37: GCC: HIV Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2011 & 2018
Figure 38: GCC: HIV Drugs (Retail Pharmacies) Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 39: GCC: HIV Drugs (Online Pharmacies) Market: Sales Value (in Million US$), 2011 & 2018
Figure 40: GCC: HIV Drugs (Online Pharmacies) Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 41: GCC: HIV Drugs (Others) Market: Sales Value (in Million US$), 2011 & 2018
Figure 42: GCC: HIV Drugs (Others) Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 43: GCC: HIV Drugs Industry: Market Dynamics
Figure 44: GCC: HIV Drugs Industry: Value Chain Analysis
Figure 45: GCC: HIV Drugs Market: Porter’s Five Forces Analysis
 
List of Tables

Table 1: GCC: HIV Drugs Market: Key Industry Highlights, 2018 and 2024
Table 2: GCC: HIV Drugs Market Outlook: Segmentation by Country (in Million US$), 2019-2024
Table 3: GCC: HIV Drugs Market Outlook: Segmentation by Drug Class (in Million US$), 2019-2024
Table 4: GCC: HIV Drugs Market Outlook: Segmentation by Distribution Channel (in Million US$), 2019-2024
Table 5: GCC: HIV Drugs Market Structure
Table 6: GCC: HIV Drugs Market: Key Players


 

Special Prices


    Syndicated Analytics provides special pricing for:

  • Academic Institutes
  • Government Agencies
  • Nonprofit Organizations

  • For more information, feel free to contact us.





Related Reports

GCC Healthcare Information Software Market by Development (On-Premise and Cloud) and Application (Hospitals, Clinics, Medical Research Centers and others):Industry Analysis, Trends, Growth and Forecast 2019-2024

The GCC Healthcare Information Software Market was worth US$ XX Billion in 2018, expanding at a CAGR of X% during 2011-2018. The market is projected to register a CAGR of X% during 2019-2024, reaching US$ XX Billion by 2024.

GCC Body Countering Market by of Invasiveness (Non-Invasive Contouring, Minimally Invasive Contouring and Invasive Contouring) and End-Use Sector (Clinical Research Organizations, Hospitals, Medical Spa and Clinics): Industry Analysis, Trends, Growth and Forecast 2019-2024

The GCC Body Countering was worth US$ XX Billion in 2018, expanding at a CAGR of X% during 2011-2018. The market is projected to register a CAGR of X% during 2019-2024, reaching US$ XX Billion by 2024.

GCC Protein Ingredients Market by Product Type (Animal Proteins and Plant Proteins) and Application (Food & Beverages, Personal Care & Cosmetics, Pharmaceuticals and Animal Feed): Industry Analysis, Trends, Growth and Forecast 2019-2024

The GCC Protein Ingredients Market was worth US$ XX Billion in 2018, expanding at a CAGR of X% during 2011-2018. The market is projected to register a CAGR of X% during 2019-2024, reaching US$ XX Billion by 2024.

GCC Takaful Market by Product (Life/Family Takaful and General Takaful): Industry Analysis, Trends, Growth and Forecast 2019-2024

The GCC Takaful Market was worth US$ XX Billion in 2018, expanding at a CAGR of X% during 2011-2018. The market is projected to register a CAGR of X% during 2019-2024, reaching US$ XX Billion by 2024.

GCC Generic Injectables Market by Therapeutic Area (Oncology, Anaesthesia, Anti-Infectives, Parenteral Nutrition and Cardiovascular) by Container (Vials, Ampoules, Premix and Prefilled Syringes) and Distribution Channel (Hospitals and Retail Pharmacy Stores): Industry Analysis, Trends, Growth and Forecast 2019-2024

The GCC Generic Injectables Market was worth US$ 438 Million in 2018, expanding at a CAGR of 14% during 2011-2018. The market is projected to register a CAGR of 12% during 2019-2024, reaching US$ US$ 865 Million Billion by 2024.